Search research articles
Contact Us
Filters
Showing results (31-40 of 63) with videos related to
Page
of 7
Sort By:
International Journal of Clinical Oncology
|
December 23, 2024
A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device
Hideaki Bando, Yoichi Naito, Tomoyuki Yamada, et al.
Cancers
|
April 3, 2021
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix
Daisuke Takayanagi, Sou Hirose, Ikumi Kuno, et al.
JCO Precision Oncology
|
May 26, 2021
Impact of ALK Inhibitors in Patients With <i>ALK</i>-Rearranged Nonlung Solid Tumors
Yuki Takeyasu, Hitomi S Okuma, Yuki Kojima, et al.
Cancer Science
|
August 17, 2022
Chronological improvement in precision oncology implementation in Japan
Kuniko Sunami, Yoichi Naito, Keigo Komine, et al.
Cancer Science
|
March 27, 2024
Identification of barriers to implementation of precision oncology in patients with rare cancers
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, et al.
Cancer Science
|
June 15, 2021
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA
Kuniko Sunami, Hideaki Bando, Yasushi Yatabe, et al.
Cancer Science
|
July 7, 2026
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort
Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi, et al.
Experimental Hematology & Oncology
|
November 1, 2022
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
Ryuji Hamamoto, Takafumi Koyama, Nobuji Kouno, et al.
Eclinicalmedicine
|
February 9, 2024
Dabrafenib and trametinib administration in patients with <i>BRAF</i> V600E/R or non-V600 <i>BRAF</i> mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial
Tatsunori Shimoi, Kuniko Sunami, Makoto Tahara, et al.
Cancer Medicine
|
August 20, 2020
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma
Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 63) with videos related to
Sort By:
Page
of 7
International Journal of Clinical Oncology
|
December 23, 2024
A prospective study comparing highly qualified Molecular Tumor Boards with AI-powered software as a medical device
Hideaki Bando, Yoichi Naito, Tomoyuki Yamada, et al.
Cancers
|
April 3, 2021
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix
Daisuke Takayanagi, Sou Hirose, Ikumi Kuno, et al.
JCO Precision Oncology
|
May 26, 2021
Impact of ALK Inhibitors in Patients With <i>ALK</i>-Rearranged Nonlung Solid Tumors
Yuki Takeyasu, Hitomi S Okuma, Yuki Kojima, et al.
Cancer Science
|
August 17, 2022
Chronological improvement in precision oncology implementation in Japan
Kuniko Sunami, Yoichi Naito, Keigo Komine, et al.
Cancer Science
|
March 27, 2024
Identification of barriers to implementation of precision oncology in patients with rare cancers
Shigemasa Takamizawa, Takafumi Koyama, Kuniko Sunami, et al.
Cancer Science
|
June 15, 2021
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA
Kuniko Sunami, Hideaki Bando, Yasushi Yatabe, et al.
Cancer Science
|
July 7, 2026
Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort
Masashi Kanai, Kuniko Sunami, Tatsunori Shimoi, et al.
Experimental Hematology & Oncology
|
November 1, 2022
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information
Ryuji Hamamoto, Takafumi Koyama, Nobuji Kouno, et al.
Eclinicalmedicine
|
February 9, 2024
Dabrafenib and trametinib administration in patients with <i>BRAF</i> V600E/R or non-V600 <i>BRAF</i> mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial
Tatsunori Shimoi, Kuniko Sunami, Makoto Tahara, et al.
Cancer Medicine
|
August 20, 2020
Phase II trial of S-1 treatment as palliative-intent chemotherapy for previously treated advanced thymic carcinoma
Yusuke Okuma, Yasushi Goto, Fumiyoshi Ohyanagi, et al.
Page
of 7